Literature DB >> 15001908

Right ventricular targeted gene transfer of a beta-adrenergic receptor kinase inhibitor improves ventricular performance after pulmonary artery banding.

Sitaram M Emani1, Ashish S Shah, Michael K Bowman, David C White, Sitaramesh Emani, Donald D Glower, Walter J Koch.   

Abstract

OBJECTIVE: Abrupt increases in right ventricular afterload occur after cardiac transplantation and pulmonary artery banding, which can result in right ventricular hypertrophy and dilatation. Right ventricular dysfunction is also accompanied by beta-adrenergic receptor desensitization. We sought to determine whether selective right ventricular expression of a transgene encoding a beta-adrenergic receptor kinase inhibitor can improve right ventricular remodeling early after pulmonary artery banding.
METHODS: Rabbits underwent pulmonary artery banding 3 days after percutaneous right coronary artery injection of empty adenovirus (n = 19), a control adenovirus containing the beta-galactosidase transgene (n = 10), or an adenovirus containing the beta-adrenergic receptor kinase inhibitor transgene (n = 14). Sham-operated animals (n = 7) underwent instrumentation without deployment of the pulmonary artery band. Right ventricular function was assessed in each rabbit before and 7 days after pulmonary artery banding. Right ventricular mass and dimensions (surface area and volume) were obtained, and biochemical analysis was performed to confirm transgene expression and to characterize beta-adrenergic receptor signaling.
RESULTS: Right ventricular mass was increased in animals treated with adenovirus containing the beta-adrenergic receptor kinase inhibitor transgene, adenovirus containing the beta-galactosidase transgene, and empty adenovirus after banding when compared with results in sham-operated animals. However, right ventricular volume and surface area, as measures of dilatation, were significantly lower in pulmonary artery banded rabbits pretreated with adenovirus containing the beta-adrenergic receptor kinase inhibitor transgene when compared with those treated with empty adenovirus or adenovirus containing the beta-galactosidase transgene. Right ventricular contractility and defective beta-adrenergic receptor signaling were significantly enhanced in rabbits expressing the beta-adrenergic receptor kinase inhibitor after pulmonary artery banding.
CONCLUSIONS: Right ventricular preconditioning with the beta-adrenergic receptor kinase inhibitor transgene can attenuate the early right ventricular dilatation and dysfunction associated with pulmonary artery banding. Thus beta-adrenergic receptor kinase inhibition might represent a novel target for limiting ventricular remodeling after increased right ventricular afterload.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001908     DOI: 10.1016/s0022-5223(03)01189-9

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  AAV6-βARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve.

Authors:  Michael G Katz; Anthony S Fargnoli; JaBaris D Swain; Catherine E Tomasulo; Michele Ciccarelli; Z Maggie Huang; Joseph E Rabinowitz; Charles R Bridges
Journal:  J Thorac Cardiovasc Surg       Date:  2011-12-03       Impact factor: 5.209

Review 2.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 3.  GRK2 as a novel gene therapy target in heart failure.

Authors:  Giuseppe Rengo; Anastasios Lymperopoulos; Dario Leosco; Walter J Koch
Journal:  J Mol Cell Cardiol       Date:  2010-08-25       Impact factor: 5.000

4.  Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis.

Authors:  Takashi Urashima; Mingming Zhao; Roger Wagner; Giovanni Fajardo; Sara Farahani; Tom Quertermous; Daniel Bernstein
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-27       Impact factor: 4.733

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.